Bizarre Patents
Mouthguard made at least partially from an edible candy
A mouthguard includes a U-shaped upper bite plate which removably fits over upper teeth of a person, with the entire upper bite plate being made from a soft, deformable and edible gummi candy.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6491906 | CXC chemokines as regulators of angiogenesis Disclosed are various discoveries concerning the angiogenic and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these molecules to induce angiogenesis. Aspects of the invention include, for ex... | 12/10/2002 |
| 6482403 | Caniney IL-13 immunoregulatory proteins and uses thereof The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins; to canine interleukin... | 11/19/2002 |
| 6479048 | Water-soluble dry compositions Provisions of a foam inhibitor which effectively inhibits foaming (bubbling) caused at the time of dissolving dry compositions and of a water-soluble dry composition which comprises the foam inhibitor. The form inhibitor is suitable for inhibiting foaming... | 11/12/2002 |
| 6479261 | Methods of using interleukin-3 (IL-3) mutant polypeptides for ex-vivo expansion of hematopoietic stem cells The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also rel... | 11/12/2002 |
| 6479634 | IL-B30 proteins Purified genes encoding cytokines from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using the reagents and diagnostic kits are also provided.... | 11/12/2002 |
| 6475490 | Compositions and methods for promoting tissue repair using heat shock proteins The invention relates to methods and compositions for the promotion of tissue repair. Specifically, compositions comprising heat shock proteins, including gp96, hsp90, and hsp70, uncomplexed or complexed noncovalently with antigenic molecules, are disclos... | 11/05/2002 |
| 6476197 | Polypeptides having interferon-γ inducing activity Disclosed are created stable polypeptides which are capable of inducing the production of interferon-gamma by immunocompetent cells. The present polypeptides contain specific amino acid sequences usually derived from the wild-type polypeptides, being capa... | 11/05/2002 |
| 6471957 | Canine IL-4 immunoregulatory proteins and uses thereof The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins; to canine interleukin... | 10/29/2002 |
| 6461604 | Crystalline IL-6 and models of the molecular structure of IL-6 Crystallographic and NMR solution structures of human IL-6 are reported. The invention provides models and systems incorporating such structures which are useful for identifying IL-6/IL-6 receptor interactions and for identification of agonists and antago... | 10/08/2002 |
| 6458350 | ULBP DNA and polypeptides The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented pepti... | 10/01/2002 |
| 6451286 | Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds Pharmaceutical compositions comprising a macromolecular pharmaceutical agent in mixed micellar form are disclosed. The mixed micelles are formed from an alkali metal alkyl sulfate, and at least three different micelle-forming compounds as described in the... | 09/17/2002 |
| 6451760 | Treatment of inflammation using a 2F1 polypeptide or an antibody thereto 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.... | 09/17/2002 |
| 6447765 | Use of cytokines and mitogens to inhibit graft versus host disease The field of the invention is generally related to pharmaceutical agents useful in treating graft-versus-host disease (GVHD) in patients that have received allogenic bone marrow transplants.... | 09/10/2002 |
| 6444202 | Processed polypeptides with IL-16 activity, processes for their production and their use A nucleic acid, which can be used to express a polypeptide with interleukin-16 activity in a prokaryotic or eukaryotic host cell, wherein the said nucleic acid codes for a polypeptide with the amino acid sequence SEQ ID NO:2 and/or a SEQ ID NO:2 N-termina... | 09/03/2002 |
| 6444201 | Treatment of alzheimer disease by modulation of synapsins The role of synapsin II in both the reformation and the maintenance of synaptic connections in cultured hippocampal neurons can be the basis of therapy for neurodegenerative disorder, particularly Alzheimer disease, which involve the disruption of synapse... | 09/03/2002 |
| 6444200 | Composition and method for dermal and transdermal administration of a cytokine A composition for transdermal administration of a cytokine is described. The composition includes a conjugate composed of a cytokine, such as an interferon, and at least one fatty acid moiety covalently attached to the cytokine. The conjugate has enhanced... | 09/03/2002 |
| 6440934 | Angiogenically effective unit dose of FGF-2 and method of use The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof i... | 08/27/2002 |
| 6436931 | Cytotoxic agents comprising taxanes and their therapeutic use A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a ... | 08/20/2002 |
| 6436390 | IL8 inhibitors Inhibitors, including antibodies, of IL8 binding to its receptors, that interact with the amino-terminal extracellular domain of the IL8 receptor and which compete with IL8 for receptor-binding, are disclosed. The inhibitors are useful modulators of IL8 r... | 08/20/2002 |
| 6436367 | Aerosol formulations for buccal and pulmonary application A mixed micellar aerosol pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, at least three micelle forming compounds, a phenol and a propellant. The micelle forming compounds are selected from t... | 08/20/2002 |
| 6436387 | Methods of ex-vivo expansion of hematopoietic cells using multivariant IL-3 hematopoiesis chimera proteins The present invention relates to methods of ex-vivo expansion of hematopoietic cells by culturing hematopoietic cells in a growth medium comprising a chimera protein which comprises a variant of human interleukin-3 (hIL-3) which contains multiple amino ac... | 08/20/2002 |
| 6433144 | Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods This invention relates to methods for isolating highly purified mixtures of natural Type I interferon from white blood cells. The invention also relates to highly-purified mixtures of Type I interferon which resemble natural Type I interferon in that the ... | 08/13/2002 |
| 6428780 | Compounds and compositions for delivering active agents Modified amino acid compounds useful in the delivery of active agents are provided. The active agents can be peptides. Methods of administration, such as oral, subcutaneous, sublingual, and intranasal administration are provided, and methods of preparatio... | 08/06/2002 |
| 6428788 | Compositions and methods for specifically targeting tumors The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell. The method involves providing a chimeric molecule comprising an effector molecule attached to a targeting molecule that specifically... | 08/06/2002 |
| 6423308 | Treatment of Kaposi's sarcoma with IL-12 Methods are provided for using IL-12 to treat Kaposi's sarcoma (KS), particularly AIDS-associated KS.... | 07/23/2002 |
| 6417158 | Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. R... | 07/09/2002 |
| 6416753 | Method for modulating apoptosis Methods for modulating programmed cell death are provided. Apoptosis, induced by a variety of stimuli, can be inhibited by blocking IL-1ଲ binding to its type-1 receptor. Additionally, IL-1ଲ had anti-apoptotic activity when added exogenously pr... | 07/09/2002 |
| 6413509 | Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors The present invention relates to methods of ex-vivo expansion of hematopoietic cells by culturing hematopoietic cells in a growth medium comprising a variant of human interleukin-3 (hIL-3), which contains multiple amino acid substitutions and which may ha... | 07/02/2002 |
| 6410009 | Pharmaceutical composition for treating hepatitis B virus (HBV) infection The invention provides a pharmaceutical composition for the treatment of hepatitis B virus (HBV) infection, comprising an amount of a soluble active agent which interacts with at least one of the binding sites between hIL6 and pS1 and between hIL6 and hep... | 06/25/2002 |
| 6410008 | Chimeric IL-10 proteins and uses thereof Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Typ... | 06/25/2002 |
| 6406855 | Methods and compositions for polypeptide engineering Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are also disclosed.... | 06/18/2002 |
| 6407218 | Method and compositions for enhancing immune response and for the production of in vitro mabs The methods and compositions of the present invention are directed to enhancing an immune response and increasing vaccine efficacy through the simultaneous or sequential targeting of specific immune system components. More particularly, specific immune co... | 06/18/2002 |
| 6403562 | Materials and methods for treating autoimmune disease The subject invention pertains to novel methods for treating autoimmune-related diseases, such as Multiple Sclerosis (MS). One embodiment of the method of the invention comprises administering interleukin-10 (IL-10) and transforming growth factor-beta (TG... | 06/11/2002 |
| 6403096 | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically jo... | 06/11/2002 |
| 6403078 | Method and compositions for treating preterm labor and premature rupture of fetal membranes Methods and compositions for the prevention and treatment of preterm labor and premature rupture of fetal membranes are provided. The methods of the invention inhibit the upregulated production of certain pro-inflammatory cytokines in amniochorionic membr... | 06/11/2002 |
| 6403077 | Treatment regimes featuring an IL-10-containing chimeric polypeptide Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, i... | 06/11/2002 |
| 6403076 | Compositions for increasing hematopoiesis with interleukin-3 mutants The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 varian... | 06/11/2002 |
| 6399077 | Method of augmenting T cell-mediated immunity against Toxoplasma gondii A method of augmenting T cell-mediated immunity against Toxoplasma gondii is provided. Immunization with Toxoplasma gondii soluble parasite antigen and exogenous rIL-15 was found to protect against Toxoplasma gondii infection.... | 06/04/2002 |
| 6399068 | Method of treatment with a non-antigenic toxin-conjugate and fusion protein of internalizing receptor system A conjugate of a toxin and a cytokine, and a fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15, each optionally further compris... | 06/04/2002 |
| 6399573 | Interleukin-1 receptor antagonist beta (IL-1rabeta) IL-1ra beta polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing IL-1ra beta polypeptides and polynucleotides in the design of protocols for the trea... | 06/04/2002 |
